Gilead Sciences/$GILD
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Gilead Sciences
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Primary listing
Employees
17,600
Headquarters
Website
Gilead Sciences Metrics
BasicAdvanced
$147B
23.60
$5.01
0.35
$3.14
2.67%
Price and volume
Market cap
$147B
Beta
0.35
52-week high
$121.83
52-week low
$84.17
Average daily volume
7.4M
Dividend rate
$3.14
Financial strength
Current ratio
1.315
Quick ratio
0.969
Long term debt to equity
113.017
Total debt to equity
127.34
Dividend payout ratio (TTM)
62.75%
Interest coverage (TTM)
11.04%
Profitability
EBITDA (TTM)
13,801
Gross margin (TTM)
78.53%
Net profit margin (TTM)
21.87%
Operating margin (TTM)
38.22%
Effective tax rate (TTM)
12.36%
Revenue per employee (TTM)
$1,640,000
Management effectiveness
Return on assets (TTM)
12.62%
Return on equity (TTM)
33.40%
Valuation
Price to earnings (TTM)
23.597
Price to revenue (TTM)
5.107
Price to book
7.47
Price to tangible book (TTM)
-20.38
Price to free cash flow (TTM)
15.733
Free cash flow yield (TTM)
6.36%
Free cash flow per share (TTM)
7.516
Dividend yield (TTM)
2.66%
Forward dividend yield
2.67%
Growth
Revenue change (TTM)
3.81%
Earnings per share change (TTM)
496.80%
3-year revenue growth (CAGR)
1.61%
10-year revenue growth (CAGR)
-0.11%
3-year earnings per share growth (CAGR)
15.28%
10-year earnings per share growth (CAGR)
-6.17%
3-year dividend per share growth (CAGR)
2.70%
10-year dividend per share growth (CAGR)
21.92%
What the Analysts think about Gilead Sciences
Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Bulls say / Bears say
Total HIV product sales rose 7% year-over-year to $5.1 billion in Q2 2025, underlining the resilience of Gilead’s core HIV franchise (Reuters)
The launch of Yeztugo, the first twice-yearly HIV prevention injection, saw rapid initial uptake—with first script written within hours and first dose delivered days after FDA approval—accelerating insurer coverage (Reuters)
Gilead expanded its oncology pipeline via a $750 million option and license agreement with Kymera Therapeutics to develop novel molecular glue degrader candidates, diversifying long-term growth drivers (Reuters)
Liver disease treatment sales fell 4% to $795 million in Q2 2025 due to declining hepatitis C drug revenues, signaling vulnerability in its HCV franchise (Reuters)
Cell therapy revenues declined by 7% to $485 million in Q2 2025 amid rising competition, reflecting pressure on Yescarta and Tecartus growth (Reuters)
Non-GAAP EPS remained flat at $2.01 in Q2 2025 despite revenue growth, indicating limited operating leverage and margin expansion (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Sept 2025.
Gilead Sciences Financial Performance
Revenues and expenses
Gilead Sciences Earnings Performance
Company profitability
Gilead Sciences News
AllArticlesVideos
Gilead Announces Partnership With PEPFAR to Deliver Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries
Business Wire1 month ago
US plans to bring Gilead HIV drug to market in high-burden HIV countries
Reuters1 month ago
Global drugmakers rush to boost US presence as tariff threat looms
Reuters1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Gilead Sciences stock?
Gilead Sciences (GILD) has a market cap of $147B as of October 09, 2025.
What is the P/E ratio for Gilead Sciences stock?
The price to earnings (P/E) ratio for Gilead Sciences (GILD) stock is 23.6 as of October 09, 2025.
Does Gilead Sciences stock pay dividends?
Yes, the Gilead Sciences (GILD) stock pays dividends to shareholders. As of October 09, 2025, the dividend rate is $3.14 and the yield is 2.67%. Gilead Sciences has a payout ratio of 62.75% on a trailing twelve-month basis.
When is the next Gilead Sciences dividend payment date?
The next Gilead Sciences (GILD) dividend payment date is unconfirmed.
What is the beta indicator for Gilead Sciences?
Gilead Sciences (GILD) has a beta rating of 0.35. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.